Cagrilintide + Semaglutide vs Retatrutide
| Attribute | Cagrilintide + Semaglutide CagriSema | Retatrutide Triple agonist (GLP-1/GIP/Glucagon) |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Amylin + GLP-1 combination weight-loss research | Triple-receptor metabolic research |
| In plain English | Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying. | Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date. |
| How it works | Semaglutide activates GLP-1 receptors for satiety and glucose control; cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. | GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation. |
| Researchers study | Obesity, weight maintenance, and combination metabolic therapy. | Obesity, hepatic steatosis, and metabolic syndrome. |
| Internet discussion | Discussed as the GLP-1/amylin answer to tirzepatide's GLP-1/GIP combination. | Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide. |
Cagrilintide + Semaglutide
Amylin + GLP-1 combination weight-loss research
Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying.
Semaglutide activates GLP-1 receptors for satiety and glucose control; cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake.
Obesity, weight maintenance, and combination metabolic therapy.
Discussed as the GLP-1/amylin answer to tirzepatide's GLP-1/GIP combination.
Cagrilintide + Semaglutide (CagriSema) is the leading GLP-1 + amylin research combination for weight loss.
Retatrutide
Triple-receptor metabolic research
Retatrutide pulls three levers — appetite, insulin response, and energy expenditure via glucagon. Trials have shown the largest weight reductions of any incretin to date.
GLP-1 reduces appetite. GIP enhances insulin response. Glucagon receptor activation increases energy expenditure and fat oxidation.
Obesity, hepatic steatosis, and metabolic syndrome.
Treated as the 'next big thing' in metabolic forums. Discussion centers on side effect profile vs tirzepatide.
Retatrutide is an investigational triple agonist showing the largest weight-loss signals in metabolic research to date.